Statins and osteoporosis: Can these lipid-lowering drugs also bolster bones?

Cleveland Clinic Journal of Medicine

Volumn 69, Issue 4, 2002, Pages 277-288

  Cruz, Abelardo C ^a   Gruber, Barry L ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; BONE MORPHOGENETIC PROTEIN; CHOLESTEROL; COMPACTIN; ESTROGEN; FLUINDOSTATIN; GERANYLTRANSFERASE; GUANOSINE TRIPHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PLACEBO; PRAVASTATIN; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SIMVASTATIN; SQUALENE;

ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE STRENGTH; CELL ACTIVATION; CELL PROLIFERATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; FEMALE; HUMAN; HYPERLIPIDEMIA; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; PATHOLOGIC FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; RAT;

EID: 0036224272     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.4.277     Document Type: Article

References (28)

1. Cholesterol-lowering drugs may boost bones
2. How many women have osteoporosis now?
3. Statins: Lower lipids and better bones?
4. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
5. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
6. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: Evidence from structure-activity relationships in J774 macrophages
7. The pharmacology of bisphosphonates and new insights into their mechanisms of action
8. Protein prenylation: Molecular mechanisms and functional consequences
9. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
10. Effect of risedronate on the risk of hip fracture in elderly women
11. Prevention of nonvertebral fractures by alendronate: A meta-analysis
12. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial
13. Stimulation of bone formation in vitro and in rodents by statins
14. Mevinolin: A highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
15. HMG-CoA reductase inhibitors and the risk of fractures
16. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients
17. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women
18. Statin use, bone mass and fracture: An analysis of two prospective studies
19. Does statin use reduce risk of fracture in postmenopausal women? Results from the Women's Health Initiative Observational Study (WHI-OS)
20. Use of statins and risk of fractures
21. Effect of pravastatin on frequency of fracture in the LIPID study: Secondary analysis of a randomised controlled trial
22. Statin drugs and the risk of fracture
23. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients
24. Oral statins and increased bone-mineral density in postmenopausal women
25. Effects of 1-year treatment with fluvastatin or pravastatin on bone
26. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
27. Statins and the risk of fracture
28. Compactin and simvastatin, but not pravastatin, induce bone morphogenetic protein-2 in human osteosarcoma cells